{"entity":{"id":"elironrasib","kind":"drug","name":"Elironrasib","aka":[],"tldr":"A next-generation KRAS G12C drug that hits the active form of the protein, from the same company as daraxonrasib.","summary":"Elironrasib is a covalent tri-complex inhibitor that binds KRAS G12C in its active, GTP-bound (ON) state, unlike the first-generation drugs sotorasib and adagrasib, which trap the inactive OFF state. Hitting the active protein is intended to produce deeper, more durable responses and to overcome the adaptive RAS reactivation that limits OFF-state inhibitors. It is being tested alone and with daraxonrasib, the pan-RAS(ON) inhibitor from the same company, in non-small-cell lung cancer, colorectal cancer and the roughly 1 to 2% of pancreatic cancers that carry G12C. It is in phase 2 with no approval yet, and whether ON-state inhibition delivers a clinically meaningful advantage over the approved G12C drugs is the open question. For a newcomer, it is a next-generation KRAS G12C drug that hits the switched-on form of the protein.","status":"phase-2","asOf":"2026-09-06","links":[{"label":"ClinicalTrials.gov: trials of Elironrasib","url":"https://clinicaltrials.gov/search?intr=RMC-6291"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","pancreatic","kras-g12c-pdac"],"sections":[],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":["revolution-medicines"],"institutions":[],"pathways":["ras-mapk"],"terms":[],"trials":["nct07397338","nct06162221","nct06128551"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"RMC-6291","modality":"Small-molecule RAS(ON) G12C-selective inhibitor","mechanism":"Covalent tri-complex inhibitor of KRAS G12C in the GTP-bound state.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/elironrasib/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","route":"/companies/revolution-medicines/"}],"pathway":[{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"}],"trial":[{"id":"nct06128551","kind":"trial","name":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","route":"/trials/nct06128551/"},{"id":"nct07397338","kind":"trial","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","route":"/trials/nct07397338/"},{"id":"nct06162221","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","route":"/trials/nct06162221/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"},{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"}],"idea":[{"id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/"}],"bottleneck":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}]}}